PARIS (EGMN) - A simple blood test could help diagnose hereditary forms of breast and ovarian cancer with BRCA1 and 2 mutations, according to data presented at the Worldwide Innovative Networking (WIN) in Personalized Cancer Medicine symposium. Such a test could obviate the need for expensive genetic sequencing of women suspected of carrying BRCA1/2 mutations, enabling faster diagnosis and rapid treatment decisions to be made. Results can be obtained in just 6 days rather than 6 weeks with current...